Peptides by condition · Heart, kidneys and lungs

Peptides studied for kidney disease

Checked against our study pages and the FDA labelsPublished by PepVault

Our library holds 3 study pages on kidney disease: 2 in people (all meta-analyses or randomized trials), and 1 in animals. They studied 3 compounds, with this many study pages each: Semaglutide 1, SS-31 1 and Ac-SDKP 1.

What the research on kidney disease looks like

Kidney disease is a slow loss of the kidneys’ ability to filter the blood, most often driven by diabetes and high blood pressure. Our study pages on it are few and varied, from a large trial in people with diabetes and kidney disease to small early studies of the kidney’s blood supply and of scarring in mice.

Kidney trials follow eGFR, an estimate of how much blood the kidneys filter each minute, and count hard events such as kidney failure, dialysis or death. Smaller studies look at oxygen and blood flow in the kidney, or at scarring in tissue.

A large trial with kidney failure as its outcome is much stronger evidence than a short pilot or a mouse study. Look at who was enrolled, because kidney disease from diabetes is not the same as kidney damage from a narrowed artery.

Our study pages on kidney disease by design: Trials in people 2, Other in people 0, Animals 1, Cells 0, of 3.Trials in people2Other in people0Animals1Cells0
How many of the 3 study pages on this condition reach each design, strongest at the top: meta-analyses and randomized trials in people, other studies in people, animals, cells.
A smiling woman with silver hair in a grey training top by a window, holding her phone

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

The 3 studies, by compound

Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.

  1. Semaglutide

    1 in people

    For kidney disease, 1 of our study pages is filed under Semaglutide: 1 randomized trial in people. It enrolled 3,533 people and was published in 2024, in N Engl J Med.

    FDA-approved, with a use tied to kidney disease on its label: Ozempic (injection) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack, stroke and kidney decline in those with heart or kidney disease; Ozempic (tablet) for blood sugar control in adults with type 2 diabetes, and lowering the risk of heart attack and stroke in those at high risk (the same label as Rybelsus). Under Rybelsus and Wegovy it is approved for other uses.

  2. SS-31

    1 in people

    For kidney disease, 1 of our study pages is filed under SS-31: 1 randomized trial in people. It was published in 2017, in Circ Cardiovasc Interv, and our page does not give its size.

    FDA-approved for other uses, not for kidney disease: Forzinity (injection) for improving muscle strength in adults and children with Barth syndrome who weigh at least 30 kg (an accelerated approval; it may depend on a confirmatory trial).

  3. Ac-SDKP

    1 in animals

    For kidney disease, 1 of our study pages is filed under Ac-SDKP: 1 animal study (mice). It was published in 2016, in Biomed Res Int.

    Ac-SDKP has no FDA-approved product: Drugs@FDA lists no application for it.

Side by side

For the 3 compounds on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).

CompoundIn peopleAnimals or cellsLargest in peopleFDA
Semaglutide103,533Approved, a use tied to it
SS-3110—Approved for other uses
Ac-SDKP01—Not approved

What the studies did not show

Each study page names its own limits. These are the questions still open, in the study pages’ words.

This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.

Questions

Which peptides have been studied for kidney disease?

Our 3 study pages on kidney disease are filed under 3 compounds, with this many each: Semaglutide 1, SS-31 1 and Ac-SDKP 1. Semaglutide, SS-31 and Ac-SDKP have the most, 1 each.

Have any been tested in people with kidney disease?

Yes: 2 of the 3 were in people, all of them meta-analyses or randomized trials (Semaglutide and SS-31). The largest enrolled 3,533 people: “Semaglutide: 24% lower risk of major kidney events in FLOW” (2024).

Is any peptide FDA-approved for kidney disease?

Yes, with a use tied to kidney disease on their FDA labels: Semaglutide as Ozempic. 2 other compounds here with an FDA record have no use tied to it.

How large were the studies in people on kidney disease?

Of the 2 in people, 1 gives its size on our pages: 1 had 1,000 people or more. The largest, a randomized trial from 2024, enrolled 3,533.

What did the animal and cell studies on kidney disease use?

1 animal study (mice), filed under Ac-SDKP. A result in animals or cells shows what to test next, not what happens in a person.

What is the newest study on kidney disease here?

Of our study pages on kidney disease, the newest is “Semaglutide: 24% lower risk of major kidney events in FLOW”, a randomized trial in people published in 2024.

How this page was built

A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.

Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.

Track it in the app

PepVault for iPhone

Track your own progress in PepVault

Doses, vials, weight and side effects in one log.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo